HCPCS Level II · Drugs administered other than oral method
J1745Injection, infliximab, excludes biosimilar, 10 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J1745
J1745 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, infliximab, excludes biosimilar, 10 mg.
It was added to HCPCS effective 01/01/2000, and its current record took effect 01/01/2017.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Infliximab not biosimil 10mg
- Date added
- 01/01/2000
- Action effective
- 01/01/2017
- BETOS
- O1E
Related J17xx codes
- J1700Injection, hydrocortisone acetate, up to 25 mg
- J1720Injection, hydrocortisone sodium succinate, up to 100 mg
- J1726Injection, hydroxyprogesterone caproate, (makena), 10 mg
- J1729Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
- J1730Injection, diazoxide, up to 300 mg
- J1736Injection, meloxicam (delova), 1 mg
- J1737Injection, meloxicam (azurity), 1 mg
- J1738Injection, meloxicam, 1 mg
- J1740Injection, ibandronate sodium, 1 mg
- J1741Injection, ibuprofen, 100 mg
- J1742Injection, ibutilide fumarate, 1 mg
- J1743Injection, idursulfase, 1 mg
Common questions about J1745
Is HCPCS J1745 still valid?
- Yes. J1745 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J1745?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.